Solute carriers (SLC) transporters-expressing cells play an important role in the absorption, distribution, and clearance of a wide variety of metabolites and drugs from the kidney and other organs. Researchers need in vitro models of transporters that have human origin, functioning transporters, clinical predictability, and consistent data output for both functional and drug interaction studies

Researchers need models of in vitro kidney transporters that have normal human kidney origin, functioning transporters, clinical predictability, and consistent data output for drug interaction studies. Unfortunately, primary renal epithelial cells lose OAT1, OCT2, and OAT3 transporter expression quickly in culture. 

ATCC has been able to utilize hTERT-immortalized primary renal proximal tubule epithelial cells to create kidney transporter cells that stably overexpress either the OAT1, OCT2, or OAT3 gene for drug toxicity screening and more.

Furthermore, in collaboration with the RESOLUTE project, ATCC has accessioned a large collection of cell lines that possess genetically deleted (Knockout, KO) SLC transporters such as SLC25, MITCH1, and SLC35. These cell lines were derived from colorectal cancer cells HCT116, and can be used to identity new biological roles for these understudied proteins.

The RESOLUTE project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777372. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.